A NASH biotech plans $75M offering, Arrowhead nabs Amgen payment and Astria raises $115M
Terns Pharmaceuticals saw its stock $TERN climb 30% on Monday on the back of Madrigal Pharmaceuticals’ Phase III win in NASH — which itself likely entered …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
